Rapidly progressive colonic dysplasia/neoplasia in a series of treated lung cancer patients: Is paclitaxel involved?

Journal of Oncology Pharmacy Practice

Volumn 19, Issue 1, 2013, Pages 82-85

  Kaur, Antarpreet ^a   Dasanu, Constantin A ^b  

^a UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

^b SAINT FRANCIS HOSPITAL AND MEDICAL CENTER   (United States)

Author keywords

cigarette smoking; immune suppression; paclitaxel; Second malignancy

Indexed keywords

ALKALINE PHOSPHATASE; BEVACIZUMAB; CARBOPLATIN; CARCINOEMBRYONIC ANTIGEN; FLUOROURACIL; PACLITAXEL;

ADULT; AGED; ARTICLE; BACKACHE; BRAIN DAMAGE; BRAIN METASTASIS; BRONCHOSCOPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER INCIDENCE; CANCER MORTALITY; CANCER STAGING; CARCINOGENESIS; CASE REPORT; CHRONIC KIDNEY FAILURE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COLON CANCER; COLON POLYP; COLONOSCOPY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CORONARY ARTERY SPASM; COUGHING; CYBERKNIFE; FEMALE; HEMOPTYSIS; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; IMMUNE DEFICIENCY; LUNG CANCER; LUNG NON SMALL CELL CANCER; MALE; MULTIPLE CYCLE TREATMENT; POLYPECTOMY; PRIORITY JOURNAL; RADIATION DOSE; SECOND CANCER; SMOKING; TREATMENT DURATION; WEIGHT REDUCTION;

AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, PHYTOGENIC; COLONIC NEOPLASMS; COLONIC POLYPS; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASMS, SECOND PRIMARY; PACLITAXEL; PRECANCEROUS CONDITIONS;

EID: 84874495679     PISSN: 10781552     EISSN: 1477092X     Source Type: Journal    
DOI: 10.1177/1078155211434854     Document Type: Article

References (16)

1. Mullins DW, Walker TM, Burger CJ, et al. Taxol-mediated changes in fibrosarcoma-induced immune cell function: modulation of anti-tumor activities. Cancer Immunol Immunother. 1997 ; 45: 20-28
2. Behr J, Nowak D In: Impact of air pollution on respiratory tract. Sheffield: ERS Journals Ltd ; 2002: 161-180.
3. Sopori ML, Kozak W. Immunomodultory effects of cigarette smoke. J Neuroimmunol. 1998 ; 83 (1-2). 148-156
4. Geng Y, Savage SM, Johnson LJ, et al. Chronic exposure to nicotine impairs antigen receptor-mediated signal transduction in lymphocytes. Toxicol Appl Pharmacol. 1995 ; 135 (2). 268-278
5. Geng Y, Savage SM, Razani-Boroujerdi S, et al. Effects of nicotine on immune response II. Chronic nicotine treatment induces T cell anergy. J Immunol. 1996 ; 156 (7). 2384-2390
6. Singh SP, Kalra R, Puttfacken P, et al. Acute and chronic nicotine exposures modulate the immune system through different pathways. Toxicol Appl Pharmacol. 2000 ; 164 (1). 65-72
7. Madretsma S, Wolters LM, Van Dijk, et al. In-vivo effect of nicotine on cytokine production by human non-adherant mononuclear cells. Eur J Gastroenterol Hepatol. 1996 ; 8 (10). 1017-1020
8. Martin RJ, Wexler RB, Day BJ, et al. Interaction between cigarette smoke and mycoplasma infection: a murine model. COPD. 2006 ; 3: 3-8
9. Tong AW, Seamour B, Lawson JM, et al. Cellular immune profile of patients with advanced cancer before and after taxane treatment. Am J Clin Oncol. 2000 ; 23 (5). 463-472
10. Hill MJ, Morson BC, Bussey HJ. Aetiology of adenoma-carcinoma sequence in large bowel. Lancet. 1978 ; 1: 245-247
11. Lieberman DA, Smith FW. Screening for colon malignancy with colonoscopy. Am J Gastroenterol. 1991 ; 86: 946-951
12. Disario JA, Foutch PG, Mai HD, et al. Prevalence and malignant potential of colorectal polyps in asymptomatic, average risk men. Am J Gastroenterol. 1991 ; 86: 941-945
13. Meriotta S, Aquillini M, Ricci A, et al. Changes in monocyte phagocytic activity after multi-agent chemotherapy in non-small cell lung cancer. Eur Rev Med Pharmacol Sci. 2002 ; 6 (4). 67-73
14. Hong-Gu J. Altered maturation of dendritic cells by taxol, an anticancer drug. J Vet Sci. 2003 ; 4 (3). 229-234
15. Sako T, Burioka N, Yasuda K, et al. Cellular immune profile in patients with non-small cell lung cancer after weekly paclitaxel therapy. Acta Oncol. 2004 ; 43 (1). 15-19
16. Tange S, Scherer MN, Graeb C, et al. Paclitaxel saves rat heart allografts from rejection by inhibition of the primed anti-donor humoral and cellular immune response: implications for transplant patients with cancer. Transplant Int. 2003 ; 16: 471-475